Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cartesian Therapeutics Inc 7495 New Horizon Way Frederick MD 21703 USA

www.cartesiantherapeutics.com Employees: 38 P: 301-348-8698

Description:

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Key Statistics

Overview:

Market Capitalization, $K 430,530
Enterprise Value, $K 654,170
Shares Outstanding, K 25,415
Annual Sales, $ 26,000 K
Annual Net Income, $ -219,710 K
Last Quarter Sales, $ 390 K
Last Quarter Net Income, $ -24,180 K
EBIT, $ -53,500 K
EBITDA, $ -52,740 K
60-Month Beta 0.63
% of Insider Shareholders 57.90%
% of Institutional Shareholders 86.95%
Float, K 10,700
% Float 42.10%
Short Volume Ratio 0.48

Growth:

1-Year Return -51.61%
3-Year Return -80.53%
5-Year Return -65.57%
5-Year Revenue Growth 2,788.89%
5-Year Earnings Growth 88.36%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.69 on 11/07/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -4.52
EPS Growth vs. Prev Qtr -227.78%
EPS Growth vs. Prev Year 473.44%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 04/05/24

RNAC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 4.31
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -6.03%
Profit Margin % -845.04%
Debt/Equity 0.00
Price/Sales 17.15
Price/Cash Flow N/A
Price/Book 499.14
Book Value/Share 0.04
Interest Coverage -83.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar